Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Total Non-Current Liabilities (2020 - 2025)

BioAtla (BCAB) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $30.2 million as the latest value for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 12.04% year-over-year to $30.2 million; the TTM value through Dec 2025 reached $30.2 million, down 12.04%, while the annual FY2025 figure was $30.2 million, 12.04% down from the prior year.
  • Total Non-Current Liabilities hit $30.2 million in Q4 2025 for BioAtla, up from $27.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $49.0 million in Q4 2023 and bottomed at $17.5 million in Q2 2024.
  • Average Total Non-Current Liabilities over 5 years is $28.4 million, with a median of $27.3 million recorded in 2025.
  • Year-over-year, Total Non-Current Liabilities crashed 50.55% in 2024 and then surged 138.5% in 2025.
  • BioAtla's Total Non-Current Liabilities stood at $23.8 million in 2021, then rose by 7.55% to $25.6 million in 2022, then surged by 91.42% to $49.0 million in 2023, then decreased by 29.89% to $34.3 million in 2024, then fell by 12.04% to $30.2 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $30.2 million, $27.3 million, and $41.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.